📊 PSTV Key Takeaways
Is Plus Therapeutics, Inc.. (PSTV) a Good Investment?
PSTV is a micro-revenue medical device company in acute financial distress, burning cash at 4x its annual revenue with only ~2.5 months of runway remaining. The company cannot cover operating expenses or debt service from operations, indicating a fundamentally broken business model requiring immediate capital injection or strategic restructuring to survive.
Why Buy Plus Therapeutics, Inc.. Stock? PSTV Key Strengths
- Maintains $4.3M cash reserve providing minimal operational runway
- Loss trajectory improved year-over-year with net loss declining 72.5%
- Operates in high-growth medical device sector with potential long-term tailwinds
PSTV Stock Risks: Plus Therapeutics, Inc.. Investment Risks
- Catastrophic cash burn of -$20.8M annually against $5.2M revenue with <3 months liquidity runway
- Grossly inadequate gross margin of 7.9% indicating either severe pricing failure or near-total operational underutilization
- Cannot service debt obligations from operations with -250.8x interest coverage, forcing reliance on cash depletion
Key Metrics to Watch
- Monthly cash burn rate and projected cash depletion date
- Revenue inflection point and gross margin recovery trajectory
- Debt covenant compliance and refinancing/capital raise announcements
Plus Therapeutics, Inc.. (PSTV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Plus Therapeutics, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
PSTV Profit Margin, ROE & Profitability Analysis
PSTV vs Healthcare Sector: How Plus Therapeutics, Inc.. Compares
How Plus Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Plus Therapeutics, Inc.. Stock Overvalued? PSTV Valuation Analysis 2026
Based on fundamental analysis, Plus Therapeutics, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Plus Therapeutics, Inc.. Balance Sheet: PSTV Debt, Cash & Liquidity
PSTV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Plus Therapeutics, Inc..'s revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.34 indicates the company is currently unprofitable.
PSTV Revenue Growth, EPS Growth & YoY Performance
PSTV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4M | -$2.9M | $-0.04 |
| Q2 2025 | $1.3M | -$2.9M | $-0.01 |
| Q1 2025 | $1.1M | -$3.3M | $-0.75 |
| Q1 2019 | $703.0K | -$3.2M | N/A |
| Q3 2018 | $467.0K | -$2.3M | N/A |
| Q2 2018 | $660.0K | -$3.7M | N/A |
| Q1 2018 | $591.0K | -$4.4M | N/A |
| Q3 2017 | $467.0K | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Plus Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PSTV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Plus Therapeutics, Inc.. (CIK: 0001095981)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PSTV
What is the AI rating for PSTV?
Plus Therapeutics, Inc.. (PSTV) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PSTV's key strengths?
Claude: Maintains $4.3M cash reserve providing minimal operational runway. Loss trajectory improved year-over-year with net loss declining 72.5%.
What are the risks of investing in PSTV?
Claude: Catastrophic cash burn of -$20.8M annually against $5.2M revenue with <3 months liquidity runway. Grossly inadequate gross margin of 7.9% indicating either severe pricing failure or near-total operational underutilization.
What is PSTV's revenue and growth?
Plus Therapeutics, Inc.. reported revenue of $5.2M.
Does PSTV pay dividends?
Plus Therapeutics, Inc.. does not currently pay dividends.
Where can I find PSTV SEC filings?
Official SEC filings for Plus Therapeutics, Inc.. (CIK: 0001095981) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PSTV's EPS?
Plus Therapeutics, Inc.. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PSTV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Plus Therapeutics, Inc.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PSTV stock overvalued or undervalued?
Valuation metrics for PSTV: ROE of -560.2% (sector avg: 15%), net margin of -429.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PSTV stock in 2026?
Our dual AI analysis gives Plus Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PSTV's free cash flow?
Plus Therapeutics, Inc..'s operating cash flow is $-20.8M, with capital expenditures of $67.0K. FCF margin is -399.8%.
How does PSTV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -429.4% (avg: 12%), ROE -560.2% (avg: 15%), current ratio 1.23 (avg: 2).